Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
Stellar sales performances are at times a mixed bag of good and bad for drug makers operating in Japan. This holds so true for US Merck’s I/O star Keytruda (pembrolizumab), which was hit by two double-digit price slashes last year,…
To read the full story
Related Article
- MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
- MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
- MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
April 6, 2023
- MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
- MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
- MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
- Kyle Tattle to Take Reins of MSD Japan from January
December 8, 2020
- MSD Japan Chief Wants Talks with Govt, Re-Pricing Rules Revisited to Help Innovation Thrive
August 6, 2020
- MSD Japan to Get Women’s Health Spinoff Organon Up and Running in October: Chief
April 7, 2020
BUSINESS
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
March 4, 2026
- Efient AGs Launched Just Ahead of 3-Month Supply Deadline
March 4, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…